secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2024-02-29T23:59:59+00:00
Accession:  0001171843-24-001068
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus Biopharma reports FY2023 net loss of $72.8M; cash runway into Q1 2026
-----------------------------------------------------------------------------

- Net loss $72.8M ($0.44/sh) vs $69.5M ($0.46/sh) in FY2022; revenue fell to $18.1M from $39.0M.
- Cash, cash equivalents and investments $132.3M at Dec 31, 2023; 2024 net cash burn guided $63-67M.
- Moderna LNP litigation claim construction held Feb 8, 2024; trial set for April 21, 2025.
- Phase 2a imdusiran combo data readouts expected H1 2024; third imdusiran Phase 2a trial to start H1 2024.
- AB-101 Phase 1a/1b preliminary data (healthy subjects) expected H1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000117184324001068/0001171843-24-001068-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000117184324001068/f8k_022924.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-001068

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer